Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
5.30
-0.20 (-3.66%)
Aug 15, 2025, 12:05 PM - Market open

Serina Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-12.59-11.145.27-2.68-1.26
Depreciation & Amortization
0.150.190.090.060.03
Other Amortization
0.020.35---
Loss (Gain) From Sale of Assets
---0-0.03
Loss (Gain) From Sale of Investments
---0.010.01
Stock-Based Compensation
3.932.60.030.010.08
Other Operating Activities
-9.22-5.81-7.940.54-0.33
Change in Accounts Receivable
---01.27
Change in Accounts Payable
0.51-1.660.39-0-0.37
Change in Unearned Revenue
0.070.07-0.15-1.61
Change in Other Net Operating Assets
1.52-1.72-0.31-0.16-0.05
Operating Cash Flow
-15.62-17.14-2.48-2.08-2.25
Capital Expenditures
-0.05-0.02-0.5-0.01-0.08
Investment in Securities
---0.990.93
Investing Cash Flow
-0.05-0.02-0.50.980.82
Long-Term Debt Issued
-3.0410.15-
Long-Term Debt Repaid
--0.17-0.05-3.69-0.01
Net Debt Issued (Repaid)
0.112.8810.051.31-0.01
Issuance of Common Stock
10.58100.0201
Other Financing Activities
4.920.34---
Financing Cash Flow
15.613.2110.071.311.08
Net Cash Flow
-0.07-3.957.090.22-0.35
Free Cash Flow
-15.68-17.16-2.98-2.09-2.34
Free Cash Flow Margin
-12059.23%-30641.07%-94.51%-352.55%-67.41%
Free Cash Flow Per Share
-1.66-2.33-0.41-0.97-1.09
Cash Interest Paid
---0.020
Levered Free Cash Flow
-6.68-7.94-0.82-1.22-
Unlevered Free Cash Flow
-6.67-7.96-0.48-1.21-
Change in Working Capital
2.1-3.320.08-0.01-0.75
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q